We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Cardiology

Journal Scan / Research · November 07, 2020

β-Blocker Use Is Associated With Reduced Mortality/Morbidity in Patients With HFrEF and Advanced Chronic Kidney Disease

Circulation: Heart Failure


Additional Info

Circulation: Heart Failure
Association Between β-Blocker Use and Mortality/Morbidity in Patients With Heart Failure With Reduced, Midrange, and Preserved Ejection Fraction and Advanced Chronic Kidney Disease
Circ Heart Fail 2020 Oct 19;[EPub Ahead of Print], EL Fu, A Uijl, FW Dekker, LH Lund, G Savarese, JJ Carrero

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading